Search
GT Biopharma Inc
GTBPAdd to Watchlist
0.290USD
-0.018-5.69%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.76MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of GT Biopharma Inc is 8.00, ranking 171 out of 385 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 8.00 and a low of 8.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.000
Target Price
+894.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
GT Biopharma Inc
GTBP
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is GT Biopharma Inc's price target?
Analysts forecast that GT Biopharma Inc's price target is USD 8.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 8.00.
How have GT Biopharma IncGTBP's recent earnings per share performed?
The market expectation was USD -0.11, while GT Biopharma IncGTBP's earnings per share (EPS) for the previous quarter was USD -2.23. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for GT Biopharma Inc?
Based on the ratings of GT Biopharma Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.